Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 9Myeloproliferative Disorders 4Myelodysplastic Syndromes 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1

Interventions

ruxolitinib 8fludarabine phosphate 3bomedemstat 3Whole-Body Irradiation 3Tacrolimus 3Specimen Handling 3Mycophenolic Acid 3Cyclophosphamide 3Biopsy 3fludarabine 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Melphalan 2Injections 2Busulfan 2venetoclax 1veliparib 1piperine 1pevonedistat 1iadademstat 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1anagrelide 1X-Rays 1Valganciclovir 1Transplantation 1Topotecan 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocythemia, Essential × Liposomes × 1 year × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡